Nrf2通过调节CYP2C9活动来改善心房动在心房动抗血栓治疗期间的心房纤维化
Liting Wu1, Zhumeng Li1, Lijuan Xu1
1Medical Laboratory, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Journal of cardiovascular pharmacology
|August 16, 2024
概括
核因子-erythroid-2相关因子2 (Nrf2) 过度表达减少了心房纤维化,并在患有心房动 (AF) 的老鼠中提高了华法林疗效. 这表明Nrf2激活可以提高AF患者抗凝固药治疗的安全性和有效性.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 心房动 (AF) 增加了中风和栓塞的风险,需要抗凝剂治疗,如华法林.
- 华法林剂量是关键的;不正确的水平可能导致出血或血栓.
- 在AF和华法林代谢中核因子-红色素-2-相关因子2 (Nrf2) 的作用尚未完全理解.
研究的目的:
- 调查Nrf2是否可以在AF大鼠模型中增强华法林疗效.
- 为了确定Nrf2是否调节细胞染色体P450家族2亚家族C成员9 (CYP2C9),一个关键的华法林代谢剂.
- 评估Nrf2对AF诱导的心房纤维化的影响.
主要方法:
- 建立了一个AF老鼠模型.
- 在心肌组织中利用Nrf2过度表达技术.
- 测量了原水平,与纤维化相关的基因表达 (原I,TGF-β1).
- 评估了血清华法林度,前列血时间 (PT) 和国际正常化比率 (INR).
主要成果:
- 在心肌组织中,AF降低了内源性Nrf2水平.
- 通过减少原蛋白和抑制纤维化标志物,nrf2过度表达显著降低了心房纤维化.
- Nrf2激活增加了CYP2C9的表达,降低了血清华法林水平,并降低了AF大鼠的PT/INR.
- Nrf2过度表达改善了AF老鼠的生存率.
结论:
- Nrf2过度表达可以防止与AF相关的纤维化,并改善存活率.
- Nrf2激活通过调节CYP2C9活性来增强华法林的治疗范围.
- 向Nrf2可能提供一种新的策略,以优化心房的抗凝剂治疗.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
467
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
467
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
800
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
800
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


